Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Thursday.

Several other research firms have also commented on RARE. SunTrust Banks, Inc. raised their price target on shares of Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, April 19th. Canaccord Genuity restated a “buy” rating and set a $100.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Thursday, March 23rd. Robert W. Baird restated an “outperform” rating and set a $90.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, April 19th. Jefferies Group LLC lowered shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating and dropped their price target for the company from $109.00 to $66.00 in a research report on Thursday, April 6th. Finally, HC Wainwright lowered shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and dropped their price target for the company from $88.00 to $72.00 in a research report on Wednesday, April 19th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $82.93.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) traded up 1.16% on Thursday, hitting $66.42. 539,473 shares of the company were exchanged. The company’s market capitalization is $2.81 billion. Ultragenyx Pharmaceutical has a 52 week low of $46.52 and a 52 week high of $91.35. The firm’s 50 day moving average is $58.65 and its 200 day moving average is $68.96.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.71) by $0.08. During the same quarter last year, the business posted ($1.35) EPS. On average, equities research analysts forecast that Ultragenyx Pharmaceutical will post ($7.02) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/06/24/ultragenyx-pharmaceutical-inc-rare-rating-increased-to-hold-at-valuengine.html.

In other Ultragenyx Pharmaceutical news, VP Theodore Alan Huizenga sold 480 shares of the stock in a transaction on Friday, May 26th. The shares were sold at an average price of $57.46, for a total transaction of $27,580.80. Following the transaction, the vice president now directly owns 9,366 shares of the company’s stock, valued at $538,170.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 10.10% of the company’s stock.

Several institutional investors have recently bought and sold shares of RARE. Fortaleza Asset Management Inc. increased its position in Ultragenyx Pharmaceutical by 148.5% in the first quarter. Fortaleza Asset Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 980 shares in the last quarter. Pacer Advisors Inc. increased its position in Ultragenyx Pharmaceutical by 22.6% in the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 560 shares in the last quarter. Strs Ohio increased its position in Ultragenyx Pharmaceutical by 10.7% in the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 300 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in Ultragenyx Pharmaceutical by 3.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 115 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV acquired a new position in Ultragenyx Pharmaceutical during the first quarter valued at $237,000. 95.38% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.